A D Anastasilakis1, S A Polyzos2, A Gkiomisi3, Z G Saridakis4, D Digkas4, I Bisbinas5, G T Sakellariou6, A Papatheodorou7, P Kokkoris7, P Makras8. 1. Department of Endocrinology, 424 General Military Hospital, Ring Road, 564 29 N.Efkarpia, Thessaloniki, Greece. anastath@endo.gr. 2. Second Medical Clinic, Department of Medicine, Ippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Department of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece. 4. Hellenic Military School of Medicine, Thessaloniki, Greece. 5. 1st Department of Orthopaedics, 424 General Military Hospital, Thessaloniki, Greece. 6. Department of Rheumatology, 424 General Military Hospital, Thessaloniki, Greece. 7. Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece. 8. Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Abstract
UNLABELLED: Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the more prominent reduction of bone turnover markers. Denosumab reversibly reduced endogenous RANKL. INTRODUCTION: We aimed to compare yearly changes in lumbar spine (LS) bone mineral density (BMD), bone turnover markers, free soluble receptor activator of nuclear factor kappaB ligand (sRANKL) and sclerostin levels between denosumab and zoledronic acid. METHODS:Postmenopausal women with low bone mass previously treated withzoledronic acid for 1 year were assigned to denosumab injection (n = 32) or zoledronic acid infusion (n = 26). Procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTx), sRANKL, and sclerostin levels were measured in serum samples obtained at baseline and 3, 6, and 12 months after denosumab injection or zoledronic acid infusion. LS BMD was measured at baseline and 12 months. RESULTS: The mean LS increase was 4.5 and 4.4% with denosumab and zoledronic acid, respectively (p = 0.560). Denosumab caused a larger decrease in CTx at 3 months (p < 0.001) and P1NP at 3 (p < 0.001), 6 (p = 0.021), and 12 months (p = 0.042). Denosumab significantly decreased sRANKL by 87.4% at 3 months (p < 0.001). Sclerostin levels were not changed with either intervention (p = 0.162 and p = 0.214, respectively). CONCLUSIONS: In patients previously treated withzoledronic acid, denosumab reduces bone turnover more than zoledronic acid, but the increases in LS BMD are comparable. Furthermore, denosumab administration results in reversible inhibition of the metabolically significant endogenous free soluble RANKL levels. Serum sclerostin is not affected by either agent.
RCT Entities:
UNLABELLED: Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the more prominent reduction of bone turnover markers. Denosumab reversibly reduced endogenous RANKL. INTRODUCTION: We aimed to compare yearly changes in lumbar spine (LS) bone mineral density (BMD), bone turnover markers, free soluble receptor activator of nuclear factor kappaB ligand (sRANKL) and sclerostin levels between denosumab and zoledronic acid. METHODS: Postmenopausal women with low bone mass previously treated with zoledronic acid for 1 year were assigned to denosumab injection (n = 32) or zoledronic acid infusion (n = 26). Procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide of type 1 collagen (CTx), sRANKL, and sclerostin levels were measured in serum samples obtained at baseline and 3, 6, and 12 months after denosumab injection or zoledronic acid infusion. LS BMD was measured at baseline and 12 months. RESULTS: The mean LS increase was 4.5 and 4.4% with denosumab and zoledronic acid, respectively (p = 0.560). Denosumab caused a larger decrease in CTx at 3 months (p < 0.001) and P1NP at 3 (p < 0.001), 6 (p = 0.021), and 12 months (p = 0.042). Denosumab significantly decreased sRANKL by 87.4% at 3 months (p < 0.001). Sclerostin levels were not changed with either intervention (p = 0.162 and p = 0.214, respectively). CONCLUSIONS: In patients previously treated with zoledronic acid, denosumab reduces bone turnover more than zoledronic acid, but the increases in LS BMD are comparable. Furthermore, denosumab administration results in reversible inhibition of the metabolically significant endogenous free soluble RANKL levels. Serum sclerostin is not affected by either agent.
Entities:
Keywords:
Bone mineral density; Bone turnover markers; Denosumab; RANKL; Sclerostin; Zoledronic acid
Authors: Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Paul D Miller; Yu-Ching Yang; Luanda Grazette; Javier San Martin; J Christopher Gallagher Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: David L Kendler; Christian Roux; Claude Laurent Benhamou; Jacques P Brown; Michael Lillestol; Suresh Siddhanti; Hoi-Shen Man; Javier San Martin; Henry G Bone Journal: J Bone Miner Res Date: 2010-01 Impact factor: 6.741
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone Journal: J Bone Miner Res Date: 2009-01 Impact factor: 6.741
Authors: Chris Recknor; Edward Czerwinski; Henry G Bone; Sydney L Bonnick; Neil Binkley; Santiago Palacios; Alfred Moffett; Suresh Siddhanti; Irene Ferreira; Prayashi Ghelani; Rachel B Wagman; Jesse W Hall; Michael A Bolognese; Claude-Laurent Benhamou Journal: Obstet Gynecol Date: 2013-06 Impact factor: 7.661
Authors: C Roux; L C Hofbauer; P R Ho; J D Wark; M C Zillikens; A Fahrleitner-Pammer; F Hawkins; M Micaelo; S Minisola; N Papaioannou; M Stone; I Ferreira; S Siddhanti; R B Wagman; J P Brown Journal: Bone Date: 2013-10-17 Impact factor: 4.398
Authors: Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacques P Brown; Edward Czerwiński; Marc-Antoine Krieg; Zulema Man; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Nadia Daizadeh; Michelle N Bradley; Andreas Grauer; Steven R Cummings; Henry G Bone Journal: J Bone Miner Res Date: 2012-03 Impact factor: 6.741
Authors: Henry G Bone; Roland Chapurlat; Maria-Luisa Brandi; Jacques P Brown; Edward Czerwinski; Marc-Antoine Krieg; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; Jose A Román Ivorra; Christian Roux; Eric Vittinghoff; Nadia S Daizadeh; Andrea Wang; Michelle N Bradley; Nathalie Franchimont; Michelle L Geller; Rachel B Wagman; Steven R Cummings; Socrates Papapoulos Journal: J Clin Endocrinol Metab Date: 2013-08-26 Impact factor: 5.958
Authors: Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres Journal: Endocrine Date: 2019-04-08 Impact factor: 3.633
Authors: Houchen Lyu; Bakr Jundi; Chang Xu; Sara K Tedeschi; Kazuki Yoshida; Sizheng Zhao; Sagar U Nigwekar; Benjamin Z Leder; Daniel H Solomon Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: L Gifre; S Ruiz-Gaspà; J L Carrasco; E Portell; J Vidal; A Muxi; A Monegal; N Guañabens; P Peris Journal: Osteoporos Int Date: 2017-06-04 Impact factor: 4.507